Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors

20229 citationsJournal Article

Authors

Good health and well-being

Published in: Targeted Oncology

Volume 17, Issue 2, pp. 125-138

Field-Weighted Citation Impact: 0.84